Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: John Rowton who wrote (22280)	6/16/1998 12:47:00 AM
From: Sleepman	Read Replies (2) \| Respond to of 32384

You're right. It is getting close to a trade. In fact, I am now fully loaded. However, I think that those who simply trade may miss it when it takes a large move--which, I think should be soon. Ligand is down right now in the setting of the entire market being down. In my impression, people are being extremely risk averse. Since it has yet to have any product sales, they see this company as one that is long on promises, but short on delivery. Well, it typically takes drugs 5-7 years to go from discovery to NDA. I think that Ligand has taken a number of candidates pretty far within that time frame, and still has time to spare. Admittedly, I would love it if they could shorten it. When posters are complaining about the narrow indications for which Ligand is applying, it illustrates their simplistic understanding of how the process works. A Kaposis indication is narrow, but it is an approval. Then, many physicians can look at the data relating ot other indications and see a relatively tolerable drug that may help their patients. The cost of defining all these indications is much higher as well as the cost of getting approval for indications where there are many other therapies. The same goes for the cutaneous T_cell lymphoma indication. So, buy in now, and trade if you want. This company has some great technology. They are all over oncology and hematology meetings, and will be making a greater presence in other arenas soon. It takes time to get this out of the lab, through the FDA, and onto the market, but when it does, traders will be left out. All that being said, I really hope the stock goes up soon. It is depressing me that it is still down. Dan